Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Neuroendocrine Tumor Clinical Trial

Official title:

Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01099540
• Other study ID #: 2009-09-090
• Status: Completed
• Phase: Phase 2
• First received: April 6, 2010
• Last updated: December 28, 2015
• Start date: April 2010
• Est. completion date: March 2013

Study information

• Verified date: December 2015
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: March 2013
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion Criteria:

• poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoid Tumor
• Neuroendocrine Tumor
• Neuroendocrine Tumors

Intervention

Drug:
• Pazopanib
Pazopanib 800 mg qd daily

Locations

Country	Name	City	State
Korea, Republic of	Samsung Cancer Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response rate		1~2 year	Yes